Aspirin, but not tirofiban prevents LPS-induced structural changes in the lung tissue.

<p><b>A:</b> Representative histological images of lungs from mice treated as indicated. <b>B:</b> Structural analyses of histological lung sections were made on based HE staining. * indicates significant difference compared to LPS-treated animals.</p

Aspirin reduces LPS-induced acute lung injury by interference with neutrophil recruitment.

<p>Mice were challenged with LPS via inhalation and sacrificed 4 hours later. Mice were treated with aspirin (100μg/g bodyweight via intraperitoneal injection) 30 min before or 1 hour after LPS exposure as indicated. <b>A:</b> Quantification of alveolar (left), interstitial (middle), and intravascular neutrophils (right) in mice treated as indicated. <b>B:</b> protein concentration (left) and FITC-dextran clearance (right), in BAL fluids in mice treated as indicated. n = 6–8 for each bar. * indicates significant difference compared to LPS-treated animals.</p

Tirofiban displays no protective effect in LPS-induced acute lung injury.

<p>Mice were challenged with LPS via inhalation and sacrificed 4 hours later. Mice were treated with tirofiban ((0.5μg/ g bodyweight via tail vein injection) 30 min before or 1 hour after LPS exposure as indicated. <b>A:</b> Quantification of alveolar (left), interstitial (middle), and intravascular neutrophils (right) in mice treated as indicated. <b>B:</b> protein concentration (left) and FITC-dextran clearance (right), in BAL fluids in mice treated as indicated. n = 6–8 for each bar. * indicates significant difference compared to LPS-treated animals.</p

Expression of platelet-derived chemokines (CCL5 (RANTES) and CXCL4 (PF4)) and NET release.

<p>Mice were challenged with LPS via inhalation and sacrificed 4 hours later. Mice were treated with tirofiban ((0.5μg/ g bodyweight via tail vein injection) 30 min before or 1 hour after LPS exposure as indicated or with aspirin (100μg/g bodyweight via intraperitoneal injection) 30 min before or 1 hour after LPS exposure as indicated. <b>A:</b> Plasma concentration of PF4 (CXCL4) after treatment as indicated. <b>B:</b> Plasma concentration of CCL5 after treatment as indicated. <b>C and D:</b> NET formation in the plasma (<b>C</b>) and supernatant of the lyzed lung (<b>D</b>). Values are presented as percentage increase of absorbance in comparison to the control group. n = 6–8 for each bar. * indicates significant difference compared to LPS-treated animals.</p

sj-docx-3-jet-10.1177_15266028231165731 – Supplemental material for Initial Clinical Experience With AneuFix Injectable Biocompatible Elastomer for Translumbar Embolization of Type 2 Endoleaks

Supplemental material, sj-docx-3-jet-10.1177_15266028231165731 for Initial Clinical Experience With AneuFix Injectable Biocompatible Elastomer for Translumbar Embolization of Type 2 Endoleaks by Stefan P. M. Smorenburg, Rutger J. Lely, Bas-Jeroen van Kelckhoven, Erik G. Vermeulen, Kak Khee Yeung, Rombout R. Kruse, Martin Kraai, Chrit M. Stassen, Michael J. Jacobs and Arjan W. J. Hoksbergen in Journal of Endovascular Therapy</p

sj-docx-2-jet-10.1177_15266028231165731 – Supplemental material for Initial Clinical Experience With AneuFix Injectable Biocompatible Elastomer for Translumbar Embolization of Type 2 Endoleaks

Supplemental material, sj-docx-2-jet-10.1177_15266028231165731 for Initial Clinical Experience With AneuFix Injectable Biocompatible Elastomer for Translumbar Embolization of Type 2 Endoleaks by Stefan P. M. Smorenburg, Rutger J. Lely, Bas-Jeroen van Kelckhoven, Erik G. Vermeulen, Kak Khee Yeung, Rombout R. Kruse, Martin Kraai, Chrit M. Stassen, Michael J. Jacobs and Arjan W. J. Hoksbergen in Journal of Endovascular Therapy</p

sj-docx-1-jet-10.1177_15266028231165731 – Supplemental material for Initial Clinical Experience With AneuFix Injectable Biocompatible Elastomer for Translumbar Embolization of Type 2 Endoleaks

Supplemental material, sj-docx-1-jet-10.1177_15266028231165731 for Initial Clinical Experience With AneuFix Injectable Biocompatible Elastomer for Translumbar Embolization of Type 2 Endoleaks by Stefan P. M. Smorenburg, Rutger J. Lely, Bas-Jeroen van Kelckhoven, Erik G. Vermeulen, Kak Khee Yeung, Rombout R. Kruse, Martin Kraai, Chrit M. Stassen, Michael J. Jacobs and Arjan W. J. Hoksbergen in Journal of Endovascular Therapy</p

Comparison of the open surgical and endovascular treatment subgroup.

<p>Comparison of the open surgical and endovascular treatment subgroup.</p

Development of endovascular and open surgical treatment of BTAI in Germany from 2002 till 2013.

<p>Development of endovascular and open surgical treatment of BTAI in Germany from 2002 till 2013.</p

Comparison of the conservative and surgical treatment subgroup.

<p>Comparison of the conservative and surgical treatment subgroup.</p